Doomed International Anti-Counterfeiting Pact Represents a ‘Lost Opportunity’

Drug Industry Daily
Following a resounding rejection of the intellectual property (IP) pact by EU members last year, the international Anti-Counterfeiting Trade Agreement (ACTA) now appears dead as the European Commission has decided not to request a judicial review of the proposed treaty.

To View This Article:


Subscribe To Drug Industry Daily